annb0t
Top 20
UniQure N.V.'s (NASDAQ: QURE) partner CSL Limited (OTC: CSLLY) has received FDA approval for Hemgenix (etranacogene dezaparvovec-drlb), a one-time gene therapy for hemophilia B. CSL licensed the exclusive global rights to Hemgenix from uniQure in May 2021. UniQure has received about $500 million so far from CSL and will also be eligible to get up to an additional $1.5 billion in commercial milestone payments and royalties. Cowen analyst Joseph Thome said that Hemgenix's price of $3.5 million is ...
>>> Read more: FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults
>>> Read more: FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults
